Prevention of Postoperative Nausea and Vomiting by Olanzapine (A Preliminary Study)

Prevention of Postoperative Nausea and Vomiting by Olanzapine (A Preliminary Study) - Prevention of Postoperative Nausea and Vomiting by Olanzapine (A Preliminary Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016710

Enrollment

Registered

2015-03-09

Start date

2015-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign gynecological diseases

Interventions

Oral olanzapine 10 mg (taken 9 p.m. on the day before the surgery) Oral olanzapine (10 mg taken 9 p.m. on the day before the surgery and 5 mg taken when leaving the ward on the day of the surgery) Ora

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who are American Society for Anesthesiologists (ASA) Physical Status I or II

Exclusion criteria

Exclusion criteria: Patients who 1) receive or are expected to receive epidural anesthesia 2) are contraindication to the use of any of the study medications 3) have diabetes 4) took antiemetics within 24h prior to the surgery 5) Emergency surgery 6) receive open surgery 7) are pregnant or lactating

Design outcomes

Primary

Measure	Time frame
The incidence of PONV during 24h after surgery	—

Countries

Japan

Contacts

Public ContactHiroyuki Seki

Keio University School of Medicine Anesthesiology

hseki@a3.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026